Biomarkers can be used to detect a change in the physiological state of a patient that correlates with the risk or progression of a disease (eg. Alzheimer’s disease) and/or to assess chemical exposure and the cumulative, adverse effects of toxicants in ecotoxicology. The discovery and the validation of new biomarkers raise many both analytical and instrumental challenges that ANABIO-MS group aims to tackle according to three objectives:

  • Development of a new strategy(hardware & software) based on visible laser photodissociation coupled to high resolution mass spectrometry to detect new biomarker candidates by simplifying peptide mixture sampling
  • Study of the structural dynamics of gas-phase isolated proteins and protein agregates by ion mobility-mass spectrometry coupling as a function of the pattern of their post-translational modifications (phosphorylation, oxidation, glycosylation)
  • Development of a new software concept and analytical procedures for highly robust multiplexed assays of proteins in human biological fluid or in sentinel species for ecotoxicology.

Besides new analytical methods to simultaneously quantify protein biomarkers and small molecules (e.g. endogenous compounds, micro-pollutants, metabolites) are developed with the Traces group in order to evaluate complex interaction effects on human health, such as those induced by mixtures of environmental contaminants

Recent highlights

  • Combination of chromatography and MS as an alternative to quantification by ELISA in ecotoxicology
  • Study of the repliement of aggregates between the Ib5 saliva protein and a tannin model for wine
  • Development of the MRM3 mode with hybrid quadrupole-linear ion trap mass spectrometry
    (patent WO/2010/136706 and start up ANAQUANT)
  • quantification of total ApoE and plasmatic E4 isoform in an Alzheimer’s patient cohort and of urinary aquaporine 2

Contact: Pr. Jérôme LEMOINE , Group leader –